These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 1637074)
21. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. Zhang X; Andren PE; Chergui K; Svenningsson P Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776 [TBL] [Abstract][Full Text] [Related]
22. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350 [TBL] [Abstract][Full Text] [Related]
23. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model. Chagniel L; Robitaille C; Lebel M; Cyr M Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042 [TBL] [Abstract][Full Text] [Related]
24. Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease. Issy AC; Padovan-Neto FE; Lazzarini M; Bortolanza M; Del-Bel E Life Sci; 2015 Mar; 125():71-8. PubMed ID: 25681528 [No Abstract] [Full Text] [Related]
25. Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease. Melamed E; Globus M; Rosenthal J; Uzzan A Adv Neurol; 1987; 45():507-10. PubMed ID: 3825730 [No Abstract] [Full Text] [Related]
27. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease. Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934 [TBL] [Abstract][Full Text] [Related]
28. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine. Dethy S; Laute MA; Damhaut P; Goldman S J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935 [TBL] [Abstract][Full Text] [Related]
29. Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease. Kelm-Nelson CA; Brauer AF; Ciucci MR Behav Brain Res; 2016 Jul; 307():54-64. PubMed ID: 27025445 [TBL] [Abstract][Full Text] [Related]
30. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease. Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071 [TBL] [Abstract][Full Text] [Related]
31. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Navailles S; Bioulac B; Gross C; De Deurwaerdère P Neurobiol Dis; 2011 Feb; 41(2):585-90. PubMed ID: 21092759 [TBL] [Abstract][Full Text] [Related]
32. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
33. GABA storage and release from direct pathway neurons account for the enhanced short-duration response of L-dopa in Parkinson's disease. Nishijima H; Tomiyama M J Neurol Sci; 2024 Jan; 456():122844. PubMed ID: 38142158 [No Abstract] [Full Text] [Related]
34. Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease? Wang S; Hu LF; Yang Y; Ding JH; Hu G Neuropharmacology; 2005 Jun; 48(7):984-92. PubMed ID: 15857625 [TBL] [Abstract][Full Text] [Related]
35. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399 [TBL] [Abstract][Full Text] [Related]
36. Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. Rampersaud N; Harkavyi A; Giordano G; Lever R; Whitton J; Whitton PS Neuropeptides; 2012 Oct; 46(5):183-93. PubMed ID: 22921965 [TBL] [Abstract][Full Text] [Related]
37. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
38. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Oiwa Y; Yoshimura R; Nakai K; Itakura T Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170 [TBL] [Abstract][Full Text] [Related]
39. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Ogawa N Eur Neurol; 1994; 34 Suppl 3():20-8. PubMed ID: 7821332 [TBL] [Abstract][Full Text] [Related]
40. L-dopa in Parkinson's disease. Horstink MW; van de Vlasakker CJ Neurology; 1991 Oct; 41(10):1709. PubMed ID: 1922837 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]